Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose,
crossover, oral bioequivalence study in human subjects under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Dr. Reddy's Laboratories Limited
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination